CAMBRIDGE, Mass.—Biotech drug maker Genzyme Corp. said Tuesday it plans to work with researchers in Florida to develop a test to help guide the treatment of patients with a type of lung cancer.
The company said it has bought the rights to research conducted at the Moffitt Cancer Center in Tampa, Fla., involving two proteins. Scientists there have shown the proteins, RRM1 and ERCC1, may predict whether patients will respond to the leading drug treatments for non-small-cell lung cancer, which represents about 30 percent of all lung cancers.
Terms of the agreement were not disclosed.
Shares of Genzyme Corp. fell 18 cents Tuesday to $78.50.
© Copyright 2008 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
rising
falling 